Evotec (EVO) Competitors $3.37 +0.07 (+2.12%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$3.38 +0.01 (+0.30%) As of 04/15/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVO vs. PCVX, RYTM, PTCT, OGN, ZLAB, ACLX, RNA, RARE, AKRO, and MORShould you be buying Evotec stock or one of its competitors? The main competitors of Evotec include Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Organon & Co. (OGN), Zai Lab (ZLAB), Arcellx (ACLX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Evotec vs. Vaxcyte Rhythm Pharmaceuticals PTC Therapeutics Organon & Co. Zai Lab Arcellx Avidity Biosciences Ultragenyx Pharmaceutical Akero Therapeutics MorphoSys Evotec (NASDAQ:EVO) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, valuation and community ranking. Is EVO or PCVX more profitable? Evotec's return on equity of 0.00% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets EvotecN/A N/A N/A Vaxcyte N/A -23.53%-22.20% Do institutionals and insiders believe in EVO or PCVX? 5.8% of Evotec shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 1.0% of Evotec shares are held by insiders. Comparatively, 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, EVO or PCVX? Evotec has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Does the media prefer EVO or PCVX? In the previous week, Vaxcyte had 4 more articles in the media than Evotec. MarketBeat recorded 10 mentions for Vaxcyte and 6 mentions for Evotec. Vaxcyte's average media sentiment score of 0.95 beat Evotec's score of 0.42 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Vaxcyte 5 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts prefer EVO or PCVX? Evotec presently has a consensus target price of $5.93, suggesting a potential upside of 76.06%. Vaxcyte has a consensus target price of $136.50, suggesting a potential upside of 351.54%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts clearly believe Vaxcyte is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Which has stronger earnings & valuation, EVO or PCVX? Evotec has higher revenue and earnings than Vaxcyte. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$777.05M1.54-$90.82MN/AN/AVaxcyteN/AN/A-$402.27M-$3.80-7.96 Does the MarketBeat Community prefer EVO or PCVX? Vaxcyte received 48 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 78.26% of users gave Vaxcyte an outperform vote while only 54.55% of users gave Evotec an outperform vote. CompanyUnderperformOutperformEvotecOutperform Votes654.55% Underperform Votes545.45% VaxcyteOutperform Votes5478.26% Underperform Votes1521.74% SummaryVaxcyte beats Evotec on 10 of the 15 factors compared between the two stocks. Remove Ads Get Evotec News Delivered to You Automatically Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVO vs. The Competition Export to ExcelMetricEvotecPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E RatioN/A6.7921.7317.82Price / Sales1.54225.96379.2094.61Price / Cash161.0865.6738.1534.64Price / Book0.995.866.464.00Net Income-$90.82M$141.86M$3.20B$247.23M7 Day Performance3.69%4.50%2.86%1.45%1 Month Performance-3.99%-12.65%-8.55%-6.24%1 Year Performance-51.93%-11.06%10.47%0.60% Evotec Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOEvotec1.4516 of 5 stars$3.37+2.1%$5.93+76.1%-53.5%$1.19B$777.05M0.004,200Upcoming EarningsGap UpPCVXVaxcyte3.2559 of 5 stars$32.51+2.9%$136.50+319.9%-51.5%$4.19BN/A-7.07160High Trading VolumeRYTMRhythm Pharmaceuticals3.8127 of 5 stars$54.96+17.1%$73.31+33.4%+54.9%$3.47B$130.13M-12.69140Positive NewsGap UpHigh Trading VolumePTCTPTC Therapeutics3.884 of 5 stars$42.82-1.0%$63.77+48.9%+82.8%$3.38B$806.78M-7.211,410Short Interest ↑Positive NewsOGNOrganon & Co.4.7985 of 5 stars$12.54-3.9%$20.80+65.9%-37.5%$3.23B$6.40B3.7610,000Short Interest ↓ZLABZai Lab2.4936 of 5 stars$28.81-9.3%$47.37+64.4%+113.9%$3.16B$398.99M-10.401,950News CoverageGap DownHigh Trading VolumeACLXArcellx1.9959 of 5 stars$56.65-3.3%$110.67+95.4%+7.8%$3.11B$107.94M-79.7980Positive NewsHigh Trading VolumeRNAAvidity Biosciences2.2667 of 5 stars$25.48-4.1%$66.69+161.7%+11.6%$3.06B$10.90M-8.85190Gap DownRAREUltragenyx Pharmaceutical4.5582 of 5 stars$32.14-0.9%$92.79+188.7%-17.6%$3.02B$560.23M-5.071,310Positive NewsAKROAkero Therapeutics4.3059 of 5 stars$35.97-2.1%$76.29+112.1%+75.3%$2.86BN/A-9.5930Positive NewsHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730 Remove Ads Related Companies and Tools Related Companies Vaxcyte Alternatives Rhythm Pharmaceuticals Alternatives PTC Therapeutics Alternatives Organon & Co. Alternatives Zai Lab Alternatives Arcellx Alternatives Avidity Biosciences Alternatives Ultragenyx Pharmaceutical Alternatives Akero Therapeutics Alternatives MorphoSys Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVO) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
